Skip to content

A multicenter, prospective, real-world study of Weifuchun capsule in the treatment of chronic Atrophic gastritis disease

A multicenter, prospective, real-world study of Weifuchun capsule in the treatment of chronic Atrophic gastritis disease

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300071902
Enrollment
Unknown
Registered
2023-05-29
Start date
2023-06-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Atrophic gastritis

Interventions

Observation Group:Routine treatment+Weifuchun capsule
Control Group:Routine treatment

Sponsors

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1)Meet the diagnostic criteria for chronic Atrophic gastritis; 2)Age: 18 years = age =75 years; 3)Gender Unlimited; 4)Sign the informed consent form and participate in the trial voluntarily.

Exclusion criteria

Exclusion criteria: 1)History of gastric cancer, high-grade intraepithelial neoplasia and other related cancers such as esophageal cancer and liver cancer; 2)H. H.pylori positive patients who refused standard therapy or did not turn negative after 4 weeks of standard therapy; 3)Allergy to known ingredients of the test drug and allergic constitution (more than 2 or more food or drug allergies) ; 4)Pregnant and lactating women, recent preparations for pregnancy; 5)The abnormal CR of renal function had clinical significance, the ALT of liver function was more than 2 times the upper limit of normal reference value; 6)Patients with severe primary heart, liver, kidney, lung, blood, nervous system diseases; 7)Patients with mental illness; 8)Patients who were not considered suitable for the study were identified by the researchers.

Design outcomes

Primary

MeasureTime frame
Histopathology scores;

Secondary

MeasureTime frame
Incidence of intestinal metaplasia, intraepithelial neoplasia, remission rate and progression rate;Improvement of main clinical symptoms (frequency, degree);Endoscopic classification of gastritis;

Countries

China

Contacts

Public ContactJi Guang,Xing Lianjun

Longhua hospital affiliated to Shanghai University of Traditional Chinese medicine

16765084@qq.com+86 158 2763 9709

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026